HomeCompareSYIEF vs JNJ

SYIEF vs JNJ: Dividend Comparison 2026

SYIEF yields 1.66% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYIEF wins by $307.00 in total portfolio value
10 years
SYIEF
SYIEF
● Live price
1.66%
Share price
$81.84
Annual div
$1.36
5Y div CAGR
26%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.6K
Annual income
$2,392.81
Full SYIEF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SYIEF vs JNJ

📍 SYIEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYIEFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYIEF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYIEF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYIEF
Annual income on $10K today (after 15% tax)
$140.73/yr
After 10yr DRIP, annual income (after tax)
$2,033.89/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $1,952.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYIEF + JNJ for your $10,000?

SYIEF: 50%JNJ: 50%
100% JNJ50/50100% SYIEF
Portfolio after 10yr
$30.4K
Annual income
$3,541.10/yr
Blended yield
11.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SYIEF
No analyst data
Altman Z
3.1
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYIEF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYIEFJNJ
Forward yield1.66%2.13%
Annual dividend / share$1.36$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR26%28%
Portfolio after 10y$30.6K$30.3K
Annual income after 10y$2,392.81$4,689.40
Total dividends collected$9.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SYIEF vs JNJ ($10,000, DRIP)

YearSYIEF PortfolioSYIEF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,909$208.61$10,592$272.30+$317.00SYIEF
2$11,940$267.98$11,289$357.73+$651.00SYIEF
3$13,121$345.41$12,123$472.89+$998.00SYIEF
4$14,487$446.98$13,141$629.86+$1.3KSYIEF
5$16,082$581.12$14,408$846.81+$1.7KSYIEF
6$17,968$759.66$16,021$1,151.60+$1.9KSYIEF
7$20,225$999.43$18,122$1,588.22+$2.1KSYIEF
8$22,965$1,324.75$20,930$2,228.20+$2.0KSYIEF
9$26,344$1,771.36$24,792$3,191.91+$1.6KSYIEF
10$30,581$2,392.81$30,274$4,689.40+$307.00SYIEF

SYIEF vs JNJ: Complete Analysis 2026

SYIEFStock

Symrise AG supplies fragrances, flavorings, cosmetic active ingredients and raw materials, and functional ingredients. It operates through two segments, Taste, Nutrition & Health, and Scent & Care. The Taste, Nutrition & Health segment provides functional ingredients and flavor solutions used in the production of food and beverages; savory flavors; natural and sustainable ingredients for food and beverage manufacturers, baby food, and dietary supplements; product solutions and services for pet food manufacturers; sustainable ingredients and services for aqua feed manufacturers to develop solutions for fish and shrimp farms; and probiotics for food supplements and functional foods. The Scent & Care segment develops, produces, and sells fragrance ingredients and compositions, aroma molecules, cosmetic ingredients, and mint flavors, as well as specific application processes for such substances. This segment's products are used by manufacturers of perfumes, personal care and cosmetic products, cleaning products, detergents, air fresheners, and oral care products. It operates in Europe, Africa, the Middle East, North America, the Asia Pacific, and Latin America. Symrise AG was founded in 1874 and is headquartered in Holzminden, Germany.

Full SYIEF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SYIEF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYIEF vs SCHDSYIEF vs JEPISYIEF vs OSYIEF vs KOSYIEF vs MAINSYIEF vs ABBVSYIEF vs MRKSYIEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.